Cardiovascular disease remains a leading global cause of death, and we break down its pathology, risk factors, and the ...
Although active cancer is recognised as a risk factor for increased bleeding, the specific bleeding risks associated with ...
Advances in the treatment of coronary artery disease remained steady in 2025, as in recent years, but the past 12 months also ...
The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...
The FDA approved the first oral GLP-1 for lowering body weight according to a press release from Novo Nordisk. Oral ...
Background The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains ...
Coronary artery disease (CAD) remains highly prevalent in the Indian population, with Indians facing a three-four times ...
The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing ...
13d
Health Canada authorizes TNKase(R) (tenecteplase) for the treatment of Acute Ischemic Stroke (AIS)
The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ - ...
Intensive treatment to control systolic blood pressure (BP) to less than 120 mmHg significantly reduced the incidence of major cardiovascular events in patients over the age of 50 with type 2 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback